Navigation Links
Publication of Shire plc's Annual Report 2008
Date:3/25/2009

venues and earnings

The Group's revenues are partly dependent on the level of reimbursement provided to the Group by governmental reimbursement schemes for pharmaceutical products. Changes to governmental policy or practices could adversely affect the Group's sales, financial condition and results of operations. In addition, the cost of treatment established by health care providers, private health insurers and other organizations, such as health maintenance organizations and managed care organizations are under downward pressure and this, in turn, could impact on the prices at which the Group can sell its products.

The market for pharmaceutical products could be significantly influenced by the following, which could result in lower prices for the Group's products and/or a reduced demand for the Group's products:

    - the ongoing trend toward managed health care, particularly in
      the US;

    - legislative proposals to reform health care and government
      insurance programs in many of the Group's markets; and

    - price controls and non-reimbursement of new and highly priced
      medicines for which the economic and therapeutic rationales are not
      established.

The prices for certain of the Group's products when commercialized, in particular products for the treatment of rare genetic diseases such as REPLAGAL and ELAPRASE, may be high compared to other pharmaceutical products. The Group may encounter particular difficulty in obtaining satisfactory pricing and reimbursement for its products, including those that are likely to have a high annual cost of therapy. The failure to obtain and maintain pricing and reimbursement at satisfactory levels for such products may adversely affect revenues and earnings.

Parallel importation occurs when an importer finds a cheaper price for a product or equivalent product on the world market and imports that product f
'/>"/>

SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Bionovo Announces Publication of Positive Phase 2 Trial Results for Menerba(TM)
2. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
3. InVitria Among Leading Innovators in Cell Culture Media According to Top Biotechnology Publication
4. BioTrends Releases TreatmentTrends(TM): US Nephrology, an Ongoing Syndicated Publication Providing Insight into Physician Perceptions and Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
5. New Publications Show Noninvasive Magnetic Resonance-Guided Focused Ultrasound to be a Potentially Safe, Effective Pain-Relieving Treatment for Bone Metastases
6. PharmSource and BioProcess Technology Consultants Announce Publication of New Market Report: Cell Culture Manufacturing Capacity: Trends and Outlook through 2013
7. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
8. Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated
9. Publication on Tregitopes in Blood Journal of October 2008
10. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
11. ABMAC Foundation Announces Publication of an Historic Volume Documenting the Creation of a National Health Care System in Taiwan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... (PRWEB) September 18, 2014 Leatherwood ... FM-4910 listed material, to stay competitive in the ... These high-performance materials ultimately impact product quality and ... and owner. , Established in 1980 in Lewisville, ... as many fabricators have left the business. Much ...
(Date:9/18/2014)... , Sept. 18, 2014 /PRNewswire/ - Oncothyreon Inc. ... of previously announced concurrent but separate underwritten offerings of ... to the public of $2.00 per share, for expected ... its Series A Convertible Preferred Stock at a price ... gross proceeds of $20 million. Each share of Series ...
(Date:9/18/2014)... September 18, 2014 SeqLL Inc., ... (tSMS™) technology, announced today the closing of a ... led by Genomic Diagnostic Technologies, will increase the ... applications. , Founded in March 2013 by Daniel ... Analyst at Helicos BioSciences, SeqLL has continued to ...
(Date:9/18/2014)... developed a new microscopy technology that allows them ... higher-than-ever resolution. , Dubbed "Complementation Activated Light Microscopy" ... are an order of magnitude finer than conventional ... of biomolecules at the nanometer scale. , In ... Nature Communications , the researchers behind CALM used ...
Breaking Biology Technology:Leatherwood Plastics Selects Vycom’s Flametec PVC-C Material to Stay Competitive in Semiconductor and Lab Equipment Industries 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3SeqLL Closes Series-A Funding Round for Expansion of Single Molecule Sequencing 2Scientists pioneer microscopy technique that yields fresh data on muscular dystrophy 2
... decision to return capital to stockholders through liquidationA ... Biotechnology Value Fund, L.P. ("BVF"), today announced ... ) voted overwhelmingly to remove the existing Board ... BVF,s nominees. The vote took place earlier today ...
... Human Genome Sciences, Inc. (Nasdaq: ... 4th Annual Citi Biotech Day will be webcast and ... (Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO )A ... present a corporate overview on Wednesday, April 1, 2009 ...
... BUDAPEST, Hungary, and PRINCETON, N.J., March 27 Zinsser ... collaboration agreement for product distribution in the territory of ... about partnering with Zinsser Analytic. Zinsser is a leader ... around the world," said Dr. Ferenc Darvas, president and ...
Cached Biology Technology:Biotechnology Value Fund, L.P. Announces Overwhelming Support to Remove the Board of Directors of Avigen, Inc. at Special Meeting of Stockholders 2Zinsser Analytic and ThalesNano Collaborate on Distributing Products 2
(Date:9/18/2014)... world, are the ideal animal in which to study ... the ocean into tens of thousands of freshwater streams ... skeleton to adapt to the new environment. , Breeding ... have turned up one of the genes that controls ... that gene,s regulation in a freshwater population is associated ...
(Date:9/17/2014)... to reproductive technologies, the justice and well-being of ... to identify key issues, articulate their values and ... most defensible ways forward. But what are the ... The Hastings Center and the Presidential Commission for ... to publish a series of essays to highlight ...
(Date:9/17/2014)... in 2000 as an EC-FP5 four-year project, delivering its ... progress and successful participations in several EC projects, as ... Network project (EU BON), to increase the general ... to extend the general dissemination of the Fauna Europaea ... has applied its novel e-Publishing tools to prepare data ...
Breaking Biology News(10 mins):Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 2Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 3Why bioethics literacy matters 2Why bioethics literacy matters 3Contributions on Fauna Europaea: Data papers as innovative model on expert involvement 2
... tungsten trioxide clusters line up molecule-by-molecule on the titanium ... raised slightly, holding forth the potential to execute catalytic ... system, a simplified version of a catalyst that would ... chemists the exact structure and reaction mechanisms of metal ...
... the leading cause of most common colds, struck two ... graft dysfunction and death. The two were part of ... significant respiratory infection from HRV in both the upper ... affects only upper airway tissue. , The research appears ...
... For years, the brain chemical dopamine has been thought of ... in a way that rewards a person or animal for ... certain drugs like cocaine and heroin amplify this effect ?an ... , Now, a new study from the University of ...
Cached Biology News:Uniform tungsten trimers stand and deliver 2Common cold virus leads to death in lung transplant patients 2Pleasure and pain: Study shows brain's 'pleasure chemical' is involved in response to pain too 2Pleasure and pain: Study shows brain's 'pleasure chemical' is involved in response to pain too 3Pleasure and pain: Study shows brain's 'pleasure chemical' is involved in response to pain too 4
Mouse monoclonal antibody raised against a partial recombinant PRKG1. NCBI Entrez Gene ID = PRKG1...
... polyclonal antibody raised against a ... Immunogen: PPP4C (NP_002711, ... partial recombinant protein with GST ... Number: NM_002720 ...
Mouse monoclonal antibody raised against a full length recombinant GPT. NCBI Entrez Gene ID = GPT...
Mouse monoclonal antibody raised against a partial recombinant CAPG. NCBI Entrez Gene ID = CAPG...
Biology Products: